| pubmed-article:8257777 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8257777 | lifeskim:mentions | umls-concept:C0175677 | lld:lifeskim |
| pubmed-article:8257777 | lifeskim:mentions | umls-concept:C1522564 | lld:lifeskim |
| pubmed-article:8257777 | lifeskim:mentions | umls-concept:C1456820 | lld:lifeskim |
| pubmed-article:8257777 | lifeskim:mentions | umls-concept:C1704675 | lld:lifeskim |
| pubmed-article:8257777 | lifeskim:mentions | umls-concept:C0032172 | lld:lifeskim |
| pubmed-article:8257777 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8257777 | pubmed:dateCreated | 1994-1-14 | lld:pubmed |
| pubmed-article:8257777 | pubmed:abstractText | The role played by platelet-activating factor (PAF) and tumor necrosis factor (TNF-alpha) in myocardial ischaemia-reperfusion injury was investigated. Pentobarbital anaesthetized rats were subjected to left main coronary artery ligation (1 h) followed by reperfusion (1 h; MI/R). Sham-operated rats were used as controls (Sham MI/R). Myocardial ischaemia-reperfusion injury produced a marked myocardial injury (necrotic area/area-at-risk = 60 +/- 5%; necrotic area/total area = 50 +/- 6%), high serum creatine phosphokinase activity (Sham MI/R = 25 +/- 10 U/ml; MI/R = 190 +/- 12 U/ml), a severe leukopenia (Sham MI/R = 10367 +/- 630 WBC x mm3; MI/R = 4123 +/- 120 WBC x mm3) and elevated myocardial myeloperoxidase activity (investigated as an index of leukocytes adhesion and accumulation) in the area-at-risk (6.2 +/- 0.5 U x 10(-3)/g tissue) and in necrotic area (6.6 +/- 0.7 U x 10(-3)/g tissue. Plasma PAF and serum TNF-alpha were significantly increased only during reperfusion. The peak of PAF plasma levels (6.5 +/- 1.2 pmol/ml) occurred earlier (15 min of reperfusion) than the peak of serum TNF-alpha (150 U/ml at 30 min of reperfusion). At the end of reperfusion, macrophage TNF-alpha was also enhanced (Sham MI/R = undetectable; MI/R = 148 +/- 12 U/ml). The administration of CV 6209, a specific PAF receptor antagonist (5 mg/kg, 5 min after occlusion), significantly reduced myocardial injury (necrotic area/area-at-risk = 27 +/- 3%, P < 0.001; necrotic area/total area = 10 +/- 2%, P < 0.001), blunted the increase in serum creatine phosphokinase (70 +/- 12 U/ml), partially restored leukopenia (8234 +/- 143 WBC x mm3) and lowered myeloperoxidase activity in area-at-risk (2.3 +/- 0.3 U x 10(-3)/g tissue; P < 0.001) and in necrotic area (2.8 +/- 0.5 U x 10(-3)/g tissue). In addition, administration of CV 6209 reduced the serum and macrophage levels of TNF-alpha. The results of this study, therefore, suggest that PAF and TNF-alpha are key mediators of myocardial ischaemia-reperfusion injury and that PAF plays a permissive role in inducing the release of other factor(s) relevant to reperfusion injury. | lld:pubmed |
| pubmed-article:8257777 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8257777 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8257777 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8257777 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8257777 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8257777 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8257777 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8257777 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8257777 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8257777 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8257777 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8257777 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:8257777 | pubmed:issn | 0921-8319 | lld:pubmed |
| pubmed-article:8257777 | pubmed:author | pubmed-author:CaputiA PAP | lld:pubmed |
| pubmed-article:8257777 | pubmed:author | pubmed-author:SaittaAA | lld:pubmed |
| pubmed-article:8257777 | pubmed:author | pubmed-author:CanalePP | lld:pubmed |
| pubmed-article:8257777 | pubmed:author | pubmed-author:BussolinoFF | lld:pubmed |
| pubmed-article:8257777 | pubmed:author | pubmed-author:AltavillaDD | lld:pubmed |
| pubmed-article:8257777 | pubmed:author | pubmed-author:SquadritoFF | lld:pubmed |
| pubmed-article:8257777 | pubmed:author | pubmed-author:CalapaiGG | lld:pubmed |
| pubmed-article:8257777 | pubmed:author | pubmed-author:CampoG MGM | lld:pubmed |
| pubmed-article:8257777 | pubmed:author | pubmed-author:ZingarelliBB | lld:pubmed |
| pubmed-article:8257777 | pubmed:author | pubmed-author:IoculanoMM | lld:pubmed |
| pubmed-article:8257777 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8257777 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:8257777 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8257777 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8257777 | pubmed:pagination | 53-65 | lld:pubmed |
| pubmed-article:8257777 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:meshHeading | pubmed-meshheading:8257777-... | lld:pubmed |
| pubmed-article:8257777 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8257777 | pubmed:articleTitle | Platelet activating factor interaction with tumor necrosis factor in myocardial ischaemia-reperfusion injury. | lld:pubmed |
| pubmed-article:8257777 | pubmed:affiliation | Institute of Pharmacology, School of Medicine, University of Messina, Italy. | lld:pubmed |
| pubmed-article:8257777 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8257777 | lld:pubmed |
